Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
PRECEF (ceforanide) is a second-generation cephalosporin antibiotic administered by injection for the treatment of bacterial infections. It works by inhibiting bacterial cell wall synthesis, making it effective against a broad spectrum of gram-positive and gram-negative organisms. This product is indicated for surgical prophylaxis and treatment of serious infections in hospitalized patients.
Mature product with LOE approaching and moderate competitive pressure (30), indicating defensive positioning and likely small, maintenance-focused commercial team.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PRECEF offers minimal career development potential with zero linked job openings, reflecting its mature, legacy status. Roles on this product focus on defensive operations and formulary management rather than growth, making it a consolidation assignment rather than a career launcher.
Worked on PRECEF at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.